Readministration of EGFR Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients after Initial Failure, What Affects its Efficacy?

Few therapeutic options are available for non-small cell lung cancer (NSCLC) after failure to primary epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Since TKI rechallenge is one of the most common salvage approaches in clinical practice, we sought to identify the independen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ze-Rui, li, Wei, Long, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381398/
https://www.ncbi.nlm.nih.gov/pubmed/25104233
http://dx.doi.org/10.1038/srep05996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381398/
https://www.ncbi.nlm.nih.gov/pubmed/25104233
http://dx.doi.org/10.1038/srep05996

Ejemplares similares